Merideth Hanks
Nurse Practitioner · Rogers, ARNPI 1124366943
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $138,840 of the $156,816 with a category attached, or 88.5%. AbbVie accounts for 88.2% of it on its own, with 19 other manufacturers making up the rest. Among nurse practitioner clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 587 payments — averaging $267.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$138K
- Biohaven Pharmaceutical Holding Company Ltd.$6K
- Pfizer$6K
- Inspire Medical Systems, Inc.$3K
- Lundbeck LLC$1K
- Jazz Pharmaceuticals Inc.$492
- plus $2K from 14 others
What the payments were for
- Consulting fees$8751%
- Speaking & faculty fees$138,84089%
- Travel & lodging$8,3795%
- Food & beverage$8,7086%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 345 | $138,285 |
| Biohaven Pharmaceutical Holding Company Ltd. | 22 | $6,297 |
| Pfizer | 55 | $5,934 |
| Inspire Medical Systems, Inc. | 20 | $2,576 |
| Lundbeck LLC | 39 | $1,421 |
| Jazz Pharmaceuticals Inc. | 19 | $492 |
| Harmony Biosciences LLC | 22 | $484 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $299 |
| Biohaven Pharmaceuticals, Inc. | 24 | $264 |
| Axsome Therapeutics, Inc. | 13 | $251 |
| ZOLL Respicardia, Inc. | 5 | $148 |
| Amgen | 3 | $72 |
| Teva Pharmaceuticals USA, Inc. | 4 | $68 |
| Lilly USA, LLC | 3 | $55 |
| Impel Pharmaceuticals Inc. | 2 | $51 |
| Merck | 2 | $43 |
| Merz Pharmaceuticals, LLC | 1 | $25 |
| Midsouth Orthopedics Inc. | 1 | $20 |
| Eisai Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$97,356
- QULIPTA$40,608
- BOTOX$17,563
- NURTEC ODT$11,497
- Inspire$1,417
- VYEPTI$960
- Inspire Upper Airway Stimulation System$752
- LUMRYZ$200
How this compares
$156,816 in reported general payments places this provider in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BotoxOnabotulinumtoxina | 141 | $181,779 |
| UbrelvyUbrogepant | 55 | $82,843 |
| Emgality PenGalcanezumab-Gnlm | 86 | $78,854 |
| QuliptaAtogepant | 61 | $68,074 |
| Emgality SyringeGalcanezumab-Gnlm | 17 | $42,027 |
| Aimovig AutoinjectorErenumab-Aooe | 49 | $37,972 |
| Nurtec OdtRimegepant Sulfate | 25 | $28,130 |
| ReyvowLasmiditan Succinate | 21 | $15,202 |
| Modafinil | 36 | $2,039 |
| RizatriptanRizatriptan Benzoate | 73 | $1,724 |
| Sumatriptan Succinate | 95 | $1,560 |
| Armodafinil | 22 | $1,354 |
| Gabapentin | 49 | $1,168 |
| Zolpidem Tartrate | 159 | $1,122 |
| Memantine Hcl | 43 | $811 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieBotox, Ubrelvy, Qulipta | $138,285 | $332,696257 claims |
| PfizerNurtec Odt | $5,934 | $28,13025 claims |
| Lilly USA, LLCReyvow | $55 | $15,20221 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 697 nurse practitioner providers in Arkansas.
Other nurse practitioner in Rogers
- Courtney RushingRogers$6K
- Angela JonesJonesboro$90K
- Tiffany McConathyHot Springs$54K
- Brenna FitzgeraldNorth Little Rock$46K
- Iris KennedyLittle Rock$22K
- Virginia LaliberteHot Springs$21K
- Julia PonderLittle Rock$21K
- Rhonda HillJonesboro$20K
- Dakota YoungFort Smith$15K
- Olivia CoxLittle Rock$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.